Design Therapeutics announced positive Phase 1/2 data from its RESTORE-FA trial showing DT-216P2 demonstrated dose-dependent clinical improvements in Friedreich ataxia patients after four weeks of treatment, including improvements in mFARS scores, upright stability, and fatigue. The drug showed comprehensive biomarker activity with 65% increase in FXN mRNA and 22-27% increase in FXN protein levels. The company plans to advance toward registrational development with updates expected in Q4 2026.

Design Therapeutics announced it will present Phase 1/2 RESTORE-FA trial data for DT-216P2, its experimental treatment for Friedreich's ataxia, on May 18, 2026. The company is advancing multiple clinical-stage programs using its GeneTAC gene-targeted chimera platform, with trials ongoing for corneal dystrophy and myotonic dystrophy treatments, and dosing expected to begin for its Huntington's disease program in the first half of 2026.

Design Therapeutics plans to initiate patient dosing for DT-818, a potential treatment for Myotonic Dystrophy Type-1, in the first half of 2026. The company has obtained ex-US regulatory clearance and is developing gene-targeted therapies for various genetic diseases.

CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. FTC Solar The Trade: FTC Solar, Inc. (NASDAQ: FTCI) Director Ahmad R Chatila acquired a total of 92,600 shares an average price of $0.55. To acquire these shares, it cost around $50,930. What’s Happening: On March 13, FTC ...

New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025

CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update.

Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround

The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Carmell Therapeutics The Trade: Carmell Therapeutics Corporation (NASDAQ: CTCX) President and CEO Randolph W Hubbell acquired a total of 2,750 shares an average price of $3.67. To acquire these shares, it cost around $10,091. What’s Happening: Carmell Therapeutics announced a merger with Axoloti Biologix. What Carmell Therapeutics Does: Carmell Therapeutics Corp is a regenerative medicine biotech company focused on leveraging our core platform technology, Plasma-based ...

RBC Capital Market downgraded Design Therapeutics Inc (NASDAQ: DSGN) from Outperform to Sector Perform with a price target of $7, down from $23. The company reported initial results from the company's Phase 1 multiple-ascending dose clinical trial of DT-216 in patients with Friedrich ataxia.  The company also announced plans to reformulate its Friedreich ataxia drug following injection site reactions in a Phase 1 study. Analysts Leonid Timashev and Brian Abrahams see signs of activity from DT-216 that confirm that the geneTAC ...Full story available on Benzinga.com

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow traded down 0.82% to 35,017.95 while the NASDAQ fell 0.77% to 13,682.54. The S&P 500, also fell, dropping, 0.87% to 4,450.59. Check This Out: LyondellBasell, Dropbox And 2 Other Stocks Insiders Are Selling   Leading and Lagging Sectors Health care shares fell by just 0.2% on Tuesday. In trading on Tuesday, energy shares dipped by 2.4%.   Top Headline The Home Depot, Inc. (NYSE: HD) reported better-than-expected results for its second quarter. The company posted a second-quarter FY23 sales decline of 2% year-on-year to $42.92 billion, beating the analyst consensus of $42.25 billion. EPS of $4.65 beat the analyst consensus of $4.46. The board of directors also authorized a new $15 billion share repurchase program effective August 15, 2023, replacing its previous authorization. Equities Trading UP Delcath Systems, Inc. (NASDAQ: DCTH) shares shot up 88% to $5.88 after the company announced FDA approval of HEPZATO KIT for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma. Shares of Novo Integrated Sciences, Inc. (NASDAQ: NVOS) got a boost, shooting 56% to $0.1107 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project. Siyata Mobile Inc. (NASDAQ: SYTA) shares were also up, gaining 32% to $4.3872 following upbeat quarterly sales.   Equities Trading DOWN F45 Training Holdings Inc. (NYSE: